Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations
Pharmacokinetic data indicated reduced neratinib clearance possibly due to CYP3A4 pathway saturation by everolimus. Combination therapy with neratinib and everolimus has a tolerable safety profile and clinical activity in ErbB-altered patients. ErbB family receptors and the PI3K pathway are commonly implicated in oncogenesis. This clinical study of neratinib and everolimus demonstrated favorable clinical activity and tolerability.
Authors
- Aung Naing (ORCID: https://orcid.org/0000-0002-4803-8513)
- Senthil Damodaran (ORCID: https://orcid.org/0000-0002-2470-0891)
- DD Karp
- P T Soliman
- Sarina A. Piha‐Paul (ORCID: https://orcid.org/0000-0001-9455-1660)
- Jordi Rodón (ORCID: https://orcid.org/0000-0001-6467-3632)
- Kanwal P. S. Raghav (ORCID: https://orcid.org/0000-0003-1311-4173)
- Hai T. Tran (ORCID: https://orcid.org/0000-0003-4065-9355)
- Timothy Anthony Yap (ORCID: https://orcid.org/0000-0002-2154-3309)
- Xiao‐Feng Le (ORCID: https://orcid.org/0000-0002-2381-5929)
- F. Meric-Bernstam
- Jo Ann Lim
- Chieh Tseng
- Ecaterina E Ileana Dumbrava (ORCID: https://orcid.org/0000-0002-1959-0536)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.104136
- Citations
- 3
- Primary Topic
- PI3K/AKT/mTOR signaling in cancer
- Type
- article
- Field-Weighted Citation Impact
- 2.42
Funders
- Cancer Prevention and Research Institute of Texas
- Puma Biotechnology
- National Institutes of Health
- University of Texas MD Anderson Cancer Center
- National Cancer Institute
- Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy